BURTON-ON-TRENT, England--(BUSINESS WIRE)--Clinigen Group plc (AIM:CLIN, ‘Clinigen’ or ‘the Group’), the global pharmaceuticals and services group, has today published its full year results for the year ended 30 June 2016.
|Year ended 30 June||2016||2015||Actual||Pro forma**|
|Reported gross profit||96.1||53.7||79%|
|Adjusted gross profit||102.1||53.7||90%||7%|
|Cash generated by operations||49.4||15.8||213%|
|Reported earnings per share||11.9p||6.5p||83%|
|Adjusted earnings per share||35.0p||28.0p||25%|
|Dividend per share||4.0p||3.4p||18%|
- Adjusted gross profit* up 90%, driven by acquisitions and organic growth
- Adjusted EPS* up 25% to 35.0p (2015: 28.0p)
- Net debt decreased £8.1m to £68.1m, after £28.5m spent on acquisitions
- Full year dividend increased 18% to 4.0p (2015: 3.4p)
- Strongest performances by Specialty Pharmaceuticals, driven by revitalisation of newer products, and CTS
- Integration of Idis and Link acquisitions substantially complete
- Acquisition of Totect and Foscavir bag line extension enhances Specialty Pharmaceuticals portfolio
Shaun Chilton to become CEO on 11 November 2016, when Peter George
(see separate announcement)
Peter George, Chief Executive Officer, said:
“The acquisition and integration of Idis and Link Healthcare have transformed the Group over the last 18 months.
“We have achieved our ambition to become the global market leader in the management and supply of both unlicensed and clinical trial medicines, and expanded our global footprint.
“Alongside the significant strategic progress, we have also delivered a strong financial performance with good levels of organic growth combining with the acquisitions to increase adjusted EPS* by 25%.
“The newer products in our Specialty Pharmaceuticals portfolio are making good progress, demonstrating the effectiveness of our revitalisation model and we saw another excellent year in the Clinical Trial Services division.”
Shaun Chilton, Chief Executive Officer-designate, added:
“We have started the new financial year well and are trading in line with our expectations.
“Our focus now is to capitalise on our international market leading positions and expanded geographical footprint, by driving organic growth and continuing to add to and progress the revitalisation of our products.”
*The adjusted results exclude share based payment costs, amortisation, non-underlying costs and include the 50% share of the unaudited results from the Joint Venture in South Africa. All figures referenced with * within this document are adjusted.
**Year on year comparisons, referred to as ‘pro forma’ are calculated from the aggregated unaudited results taken from i) 12 monthly management information for Clinigen and Idis, and ii) for Link Healthcare, the eight months ended 30 June 2016 and for the eight months ended 30 June 2015. The pro forma calculation has also removed the effect of the termination of the Global Access low margin contract in November 2015.
An analyst briefing will be held at 9:00am on Wednesday, 28 September 2016 at the offices of Instinctif Partners, 65 Gresham Street, London EC2V 7NQ. An audio replay file will be made available shortly afterwards via the Group’s website: www.clinigengroup.com.
For the full release, please visit the Group website at www.clinigengroup.com
About Clinigen Group
Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and services company with a unique combination of businesses focused on providing access to medicines. Its mission is to deliver the right medicine to the right patient at the right time and is focused in three areas of global medicine supply; clinical trial, unlicensed and licensed medicines.
Clinigen Clinical Trial Services is the global market leader in the management and supply of commercial medicines for clinical trials.
The Group is also the trusted global leader in ethically sourcing and supplying unlicensed medicines to hospital pharmacists and physicians for patients with a high unmet need, through three of its divisions: Idis Managed Access runs early access programs for innovative new medicines. Idis Global Access and Link Healthcare work directly with healthcare professionals to enable compliant access to unlicensed medicines on a global basis and niche essential licensed and generic medicines across Australasia, Africa and Asia (AAA region).
Clinigen Specialty Pharmaceuticals acquires global rights, revitalises and markets its own portfolio of niche hospital medicines.
For more information, please visit www.clinigengroup.com
This announcement contains certain projections and other forward-looking statements with respect to the financial condition, results of operations, businesses and prospects of Clinigen Group plc. These statements are based on current expectations and involve risk and uncertainty because they relate to events and depend upon circumstances that may or may not occur in the future. There are a number of factors which could cause actual results or developments to differ materially from those expressed or implied by these forward-looking statements. Any of the assumptions underlying these forward-looking statements could prove inaccurate or incorrect and therefore any results contemplated in the forward-looking statements may not actually be achieved. Recipients are cautioned not to place undue reliance on any forward-looking statements contained herein. Except as required by law, Clinigen undertakes no obligation to update or revise (publicly or otherwise) any forward-looking statement, whether as a result of new information, future events or other circumstances.